ベーチェット病 - 市場考察、疫学、市場予測（2032年）

主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）のベーチェット病の市場規模は、2021年に約9,500万米ドルでした。

当レポートでは、ベーチェット病の主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 ベーチェット病市場の概要

• ベーチェット病の市場シェア分布（2019年）
• ベーチェット病の市場シェア分布（2032年）

第4章 ベーチェット病のエグゼクティブサマリー

第5章 主な出来事

第6章 疫学と市場調査手法

第7章 疾患の背景と概要

• イントロダクション
• 臨床症状
  • 臨床的特徴
• 病因
  • 遺伝的要因
  • 後生的要因
  • 環境病因
  • 免疫学的経路
• 診断
  • 診断アルゴリズム
  • 鑑別診断
• 治療
  • 治療アルゴリズム

第8章 疫学と患者数

• 主な調査結果
• 主要7市場のベーチェット病の診断された有病例の合計
• 前提条件と根拠
• 米国
  • 米国のベーチェット病の診断された有病例
  • 米国のベーチェット病の診断例：発症年齢別
  • 米国のベーチェット病に関連する臨床症状
• 欧州4ヶ国・英国
  • 欧州4ヶ国・英国のベーチェット病の診断された有病例
  • 欧州4ヶ国・英国のベーチェット病の診断例：発症年齢別
  • 欧州4ヶ国・英国のベーチェット病に関連する臨床症状
• 日本
  • 日本のベーチェット病の診断された有病例
  • 日本のベーチェット病の診断例：発症年齢別
  • 日本のベーチェット病に関連する臨床症状

第9章 ペイシェントジャーニー

第10章 上市済みの治療法

第11章 ベーチェット病：主要7市場の分析

• 主な調査結果
• 主要7市場のベーチェット病の総市場規模
• 市場の見通し
• 主な市場の予測の前提条件
• 米国の市場規模
  • 米国のベーチェット病の総市場規模
  • 米国のベーチェット病の市場規模：治療法別
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のベーチェット病の総市場規模
  • 欧州4ヶ国・英国のベーチェット病の市場規模：治療法別
• 日本の市場規模
  • 日本のベーチェット病の総市場規模
  • 日本のベーチェット病の市場規模：治療法別

第12章 KOLの見解

第13章 SWOT分析

第14章 アンメットニーズ

第15章 市場参入

• 米国
  • メディケア、メディケイド
  • 民間保険
  • 患者アクセスプログラム
• 医療技術の評価
  • HAS
  • IQWIG
  • AEMPS

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Summary of Behcet's syndrome, Market, Epidemiology, and Key Events (2019-2032)
• Table 2: Key Events
• Table 3: Diagnostic System for Behcet's syndrome
• Table 4: EULAR Recommendations for the Management of Behcet's syndrome
• Table 5: JSBD Clinical Practice Guidelines for Behcet's syndrome
• Table 6: Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM (2019-2032)
• Table 7: Diagnosed Prevalent Cases of Behcet's Syndrome in the United States (2019-2032)
• Table 8: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the United States (2019-2032)
• Table 9: Clinical Manifestations Associated With Behcet's Syndrome in the US (2019-2032)
• Table 10: Diagnosed Prevalent cases of Behcet's Syndrome in EU4 and the UK (2019-2032)
• Table 11: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in EU4 and the UK (2019-2032)
• Table 12: Clinical Manifestations Associated With Behcet's Syndrome in EU4 and the UK (2019-2032)
• Table 13: Diagnosed Prevalent Cases of Behcet's Syndrome in Japan (2019-2032)
• Table 14: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in Japan (2019-2032)
• Table 15: Clinical Manifestations Associated with Behcet's Syndrome in Japan (2019-2032)
• Table 16: Key Cross of Marketed Products
• Table 17: List of Patents for OTEZLA
• Table 18: Total Market Size of Behcet's Syndrome in the 7MM in USD million (2019-2032)
• Table 19: Key Market Forecast Assumptions for OTEZLA
• Table 20: Market Size of Behcet's Syndrome in the United States in USD million (2019-2032)
• Table 21: Market Size of Behcet's Syndrome in the United States by Therapies in USD million (2019-2032)
• Table 22: Market Size of Behcet's Syndrome in EU4 and the UK in USD million (2019-2032)
• Table 23: Market Size of Behcet's Syndrome in EU4 and the UK by Therapies in USD million (2019-2032)
• Table 24: Market Size of Behcet's Syndrome in Japan in USD million (2019-2032)
• Table 25: Market Size of Behcet's Syndrome in Japan by Therapies in USD million (2019-2032)

List of Figures

• Figure 1: Symptoms of Behcet's syndrome
• Figure 2: Pathogenesis of Behcet's syndrome
• Figure 3: Diagnostic Criteria for Behcet's syndrome (ISG, ITR-ICBD, and PEDBD)
• Figure 4: Procedure of Pathergy Test
• Figure 5: Histopathologic Findings of Vasculitis in Behcet's syndrome
• Figure 6: MRI Findings of Brainstem Involvement in Behcet's syndrome
• Figure 7: Japanese Diagnostic Criteria for Systemic (partial) and Intestinal Behcet's syndrome
• Figure 8: Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM (2019-2032)
• Figure 9: Diagnosed Prevalent Cases of Behcet's Syndrome in the United States (2019-2032)
• Figure 10: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the United States (2019-2032)
• Figure 11: Clinical Manifestations Associated With Behcet's Syndrome in the US (2019-2032)
• Figure 12: Diagnosed Prevalent Cases of Behcet's Syndrome in EU4 and the UK (2019-2032)
• Figure 13: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in EU4 and the UK (2019-2032)
• Figure 14: Clinical Manifestations Associated With Behcet's Syndrome in EU4 and the UK (2019-2032)
• Figure 15: Diagnosed Prevalence of Behcet's Syndrome in Japan (2019-2032)
• Figure 16: Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in Japan (2019-2032)
• Figure 17: Clinical Manifestations Associated with Behcet's Syndrome in Japan (2019-2032)
• Figure 18: Total Market Size of Behcet's Syndrome in the 7MM (2019-2032)
• Figure 19: Market Size of Behcet's Syndrome in the United States (2019-2032)
• Figure 20: Market Size of Behcet's Syndrome in the United States by Therapies (2019-2032)
• Figure 21: Market Size of Behcet's Syndrome in EU4 and the UK (2019-2032)
• Figure 22: Market Size of Behcet's Syndrome in EU4 and the UK by Therapies (2019-2032)
• Figure 23: Market Size of Behcet's Syndrome in Japan (2019-2032)
• Figure 24: Market Size of Behcet's Syndrome in Japan by Therapies (2019-2032)

DelveInsight's 'Behcet's Syndrome - Market Insights, Epidemiology, and Market Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Behcet's syndrome in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom.

The Behcet's syndrome market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Behcet's syndrome market size from 2019 to 2032, segmented by the 7MM. The report also covers the current Behcet's syndrome treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

Study period: 2019-2032

Behcet's Syndrome: Disease Understanding and Treatment Algorithm

Behcet's Syndrome Overview

According to American Behcet's Disease Association (ABDA) and National Organization for Rare Disorders (NORD), Behcet's syndrome/Behcet's disease (BD) is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. In 1937, Turkish dermatologist Hulusi Behcet called attention to the association of oral and genital ulcerations with hypopyon-uveitis. Since then, Behcet's syndrome has become associated with several additional clinical manifestations, each attributed to an underlying vasculitis affecting vessels of all sizes.

The disease is recognized worldwide, but there are significant differences in the epidemiological, genetic, and clinical characteristics of the disorder between ethnic groups and in different geographic locations. As there are no specific manifestations nor specific diagnostic tests, the term Behcet's syndrome is preferred by some authors, especially for patients from low-prevalence areas whose disease manifestations are generally less severe and possibly due to other underlying conditions. The disease is associated with significant morbidity and mortality. The morbidity of Behcet's syndrome comes primarily from ocular involvement, and mortality relates primarily to large vessel involvement and central nervous system disease.

Treatment is dependent on the site and severity of manifestations; OTEZLA (apremilast), an oral selective phosphodiesterase 4 (PDE4) inhibitor, is the first and only approved treatment by the US Food and Drug Administration (FDA) for oral ulcers associated with Behcet's syndrome. OTEZLA was approved in 2019 as a 30 mg twice-daily therapy for adult patients in the US. In Japan, infliximab (2007) and HUMIRA (adalimumab; 2013) were approved for managing systemic and intestinal Behcet's syndrome, and TNF inhibitors are considered the drug of choice in refractory cases of the disease. Pharmacological management involves using various off-label therapies like corticosteroids and other immunosuppressants. Surgery is usually indicated for treating systemic arterial aneurysms because of the risk of rupture, but isolated arterial occlusions may be asymptomatic and not require surgery.

Behcet's syndrome Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in the Behcet's syndrome market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Behcet's syndrome Epidemiology

The Behcet's syndrome epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of KOL. The report also provides the prevalent patient pool, trends, and assumptions.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Behcet's syndrome epidemiology segmented as the diagnosed prevalent cases of Behcet's syndrome, cases of Behcet's syndrome based on the age of onset, and clinical manifestations associated with Behcet's syndrome. The report includes the diagnosed prevalent Behcet's syndrome scenario in the 7MM covering the United States, Japan, EU4 (Germany, France, Italy, Spain), and the United Kingdom) from 2019 to 2032.

Country-wise, Behcet's syndrome Epidemiology

The epidemiology segment also provides Behcet's syndrome epidemiology data and findings across the United States, Japan, EU4 (Germany, France, Italy, Spain), and the United Kingdom.

The total diagnosed prevalent patient population of Behcet's syndrome in the 7MM countries was approximately 69,000 cases in 2021.

As per the estimates, Japan had the highest prevalent patient population of Behcet's syndrome in 2021. Among the EU4 countries, Italy had the highest diagnosed patient population of Behcet's syndrome, with over 6,000 cases, followed by France in 2021. On the other hand, Germany had the lowest diagnosed prevalent patient population of Behcet's syndrome, with ~1,000 cases in 2021.

Behcet's syndrome Drug Chapters

The drug chapter segment of the Behcet's syndrome report encloses a detailed analysis of Behcet's syndrome marketed drugs and late-stage (Phase III, Phase II/III, and Phase II) pipeline drugs. It also helps understand Behcet's syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

A holistic approach to management is required involving the relevant specialists owning to the complex nature of the disease and multisystem involvement. The pharmacological and nonpharmacological approach is essential for management. With the absence of large randomized controlled clinical trials to evaluate the effects of various interventions in Behcet's syndrome, treatment is driven by recommendations of expert bodies like EULAR, with consensus statements. The main challenge in treating Behcet's syndrome is access to therapies that can effectively treat certain disease manifestations. Most treatment options for Behcet's syndrome, including oral, topical, IV, and SC injection therapies, are off-label. Despite optimal immunosuppressive treatments for Behcet's syndrome, relapses are common, and disease-related damage develops in a significant subgroup of patients, especially those with ocular, vascular, and neurological involvement. In addition, underdiagnosis, misdiagnosis, and obscure pathogenesis can threaten the management of the disease.

Products detail in the report…

Behcet's syndrome Emerging Drugs

The company currently working on Behcet's syndrome is Amgen, and it is conducting a Phase III clinical trial in pediatric patients (2 to <18 years) to estimate the efficacy of OTEZLA (apremilast) to treat oral ulcers associated with Behcet's syndrome.

OTEZLA (Amgen) is a small oral molecule and is the first and only FDA-approved treatment for oral ulcers associated with Behcet's syndrome. It acts by inhibiting PDE4 specific for cyclic adenosine monophosphate (cAMP). The drug is already approved in adults for treating oral ulcers associated with Behcet's syndrome.

Products detail in the report…

Behcet's syndrome Market Outlook

The Behcet's syndrome market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Behcet's syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Behcet's syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market, and KOL view. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

As per DelveInsight, the Behcet's syndrome market in the 7MM is expected to change in 2019-2032.

Key Findings

This section includes a glimpse of the Behcet's syndrome market in the 7MM, and the Behcet's syndrome market size was approximately USD 95 million in 2021.

The United States: Market Outlook

This section provides the total Behcet's syndrome market size and the market size of Behcet's syndrome by therapies in the United States.

The United States accounts for the highest market size of Behcet's syndrome than Japan, EU4, and the United Kingdom.

EU4 and the UK: Market Outlook

This section provides the total Behcet's syndrome market size. It also provides Behcet's syndrome market size by therapies in Germany, France, Italy, Spain, and the United Kingdom.

Japan Market Outlook

This section provides the total Behcet's syndrome market size. It also provides the market size of Behcet's syndrome by therapies in Japan.

Behcet's syndrome Drugs Uptake

This section focuses on potential drugs launched or expected to be launched in the market during 2019-2032. The analysis covers Behcet's syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and making financial and regulatory decisions.

Behcet's syndrome Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II. It also analyses Behcet's syndrome's key players in developing targeted therapeutics.

The major player in Behcet's syndrome is Amgen, whose key product for the pediatric population is expected to be launched in the US market by 20XX.

Pipeline Development Activities

The report covers collaborations, acquisitions, mergers, licensing, and patent details for emerging Behcet's syndrome therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the Behcet's syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging treatment patterns or Behcet's syndrome market trends. This will support the clients in potential novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a competitive and market intelligence analysis of the Behcet's syndrome market using various competitive intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers a descriptive overview of Behcet's syndrome, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
• Comprehensive insight is provided into Behcet's syndrome epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of the current and emerging therapies for Behcet's syndrome is provided, along with the assessment of new therapies that will impact the current treatment landscape.
• A detailed review of the Behcet's syndrome market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Behcet's syndrome market.

Report Highlights:

• Recently, the Behcet's syndrome market is set to change due to the rising awareness of the disease and incremental healthcare spending worldwide, which would expand the market size to enable drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Behcet's syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Behcet's syndrome. The launch of emerging therapies will significantly impact Behcet's syndrome market.
• For Behcet's syndrome, a better understanding of disease pathogenesis will also contribute to developing novel therapeutics.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the R&D activities.

Behcet's syndrome Report Insights

• Patient Population
• Therapeutic Approaches
• Behcet's syndrome Pipeline Analysis
• Behcet's syndrome Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Behcet's syndrome Report Key Strengths

• 11-year Forecast
• 7MM Coverage
• Behcet's syndrome Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake

Behcet's syndrome Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was the market share percentage distribution, and how would it look by 2032?
• What would be the total market size and market size of Behcet's syndrome by therapies across the 7MM forecast period (2019-2032)?
• What are the key findings about the market across 7MM, and which country will have the largest Behcet's syndrome market size during the forecast period (2019-2032)?
• At what CAGR is the Behcet's syndrome market expected to grow in the 7MM forecast period (2019-2032)?
• What would be the Behcet's syndrome market outlook across the 7MM forecast period (2019-2032)?
• What would be the Behcet's syndrome market growth until 2032 and the resultant market size by 2032?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Behcet's syndrome?
• What is the historical patient pool of Behcet's syndrome covering the United States, Japan, EU4 (Germany, Spain, France, Italy), and the UK?
• What would be the forecasted patient pool of Behcet's syndrome covering the United States, Japan, EU4 (Germany, Spain, France, Italy), and the UK?
• What will be the growth opportunities in the 7MM concerning the patient population of Behcet's syndrome?
• Out of all the 7MM, which country would have the highest prevalence of Behcet's syndrome during the forecast period (2019-2032)?
• At what CAGR is the population expected to grow in the 7MM forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options to treat Behcet's syndrome?
• What are the current treatment guidelines for treating Behcet's syndrome in the US, Europe, and Japan?
• What are the Behcet's syndrome marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies to treat Behcet's syndrome?
• How many therapies are developed by each company to treat Behcet's syndrome?
• How many emerging therapies are in the mid-stage and late stages of development to treat Behcet's syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to Behcet's syndrome therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies for Behcet's syndrome and its status?
• Which key designations have been granted for the emerging therapies for Behcet's syndrome?
• What are the global historical and forecasted Behcet's syndrome markets?

Reasons to buy:

• The report will help develop business strategies by understanding trends shaping and driving the Behcet's syndrome market.
• To understand the future market competition in the Behcet's syndrome market and an insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Behcet's syndrome in the US, Europe (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
• Identifying upcoming solid players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Behcet's syndrome market.
• To understand the future market competition in the Behcet's syndrome market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Behcet's Syndrome Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Behcet's Syndrome in 2019
• 3.2. Market Share (%) Distribution of Behcet's Syndrome in 2032

4. Executive Summary of Behcet's Syndrome

5. Key Events

6. Epidemiology and Market Methodology

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Clinical Manifestations
  • 7.2.1. Clinical features
    • 7.2.1.1. Oral lesions
    • 7.2.1.2. Genital lesions
    • 7.2.1.3. Skin lesions
    • 7.2.1.4. Ocular manifestations
    • 7.2.1.5. Arthritis
    • 7.2.1.6. Gastrointestinal involvement
    • 7.2.1.7. Respiratory involvement
    • 7.2.1.8. Central nervous system/neurological involvement
    • 7.2.1.9. Other symptoms
• 7.3. Etiopathogenesis
  • 7.3.1. Genetic factors
  • 7.3.2. Epigenetic factors
  • 7.3.3. Environmental etiology
  • 7.3.4. Immunological pathway
• 7.4. Diagnosis
  • 7.4.1. Diagnostic algorithm
    • 7.4.1.1. The Japanese society consensus statement for the diagnosis of intestinal Behcet's syndrome
  • 7.4.2. Differential diagnosis
• 7.5. Treatment
  • 7.5.1. Treatment algorithm
    • 7.5.1.1. European League Against Rheumatism (EULAR) Recommendations for the Management of Behcet Disease
    • 7.5.1.2. Consensus Statements for the Diagnosis and Management of Intestinal Behcet Disease by the Japanese Society for Behcet Disease

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Total Diagnosed Prevalent Cases of Behcet's Syndrome in the 7MM
• 8.3. Assumptions and Rationale
• 8.4. The United States
  • 8.4.1. Diagnosed Prevalent Cases of Behcet's Syndrome in the United States
  • 8.4.2. Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in the United States
  • 8.4.3. Clinical Manifestations Associated with Behcet's Syndrome in the US
• 8.5. EU4 and the UK
  • 8.5.1. Diagnosed Prevalent Cases of Behcet's Syndrome in EU4 and the UK
  • 8.5.2. Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in EU4 and the UK
  • 8.5.3. Clinical Manifestations Associated with Behcet's Syndrome in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Diagnosed Prevalent Cases of Behcet's Syndrome in Japan
  • 8.6.2. Diagnosed Cases of Behcet's Syndrome Based on the Age of Onset in Japan
  • 8.6.3. Clinical Manifestations Associated with Behcet's Syndrome in Japan

9. Patient Journey

10. Marketed Therapies

• 10.1. Key cross: Marketed Products
• 10.2. OTEZLA (apremilast): Amgen
  • 10.2.1. Drug description
  • 10.2.2. Regulatory milestones
  • 10.2.3. Other development activities
  • 10.2.4. Safety and efficacy
  • 10.2.5. Side effects
  • 10.2.6. Product profile
  • 10.2.7. Analysts' comments
• 10.3. REMICADE (infliximab): Janssen Pharmaceutical/Mitsubishi Tanabe Pharma
  • 10.3.1. Drug description
  • 10.3.2. Regulatory milestones
  • 10.3.3. Other development activities
  • 10.3.4. Safety and efficacy
  • 10.3.5. Side effects
  • 10.3.6. Product profile
• 10.4. HUMIRA (adalimumab): AbbVie/Eisai
  • 10.4.1. Drug description
  • 10.4.2. Regulatory milestones
  • 10.4.3. Other development activities
  • 10.4.4. Safety and efficacy
  • 10.4.5. Side effects
  • 10.4.6. Product profile

11. Behcet's Syndrome: The 7MM Analysis

• 11.1. Key Findings
• 11.2. Total Market Size of Behcet's Syndrome in the 7MM
• 11.3. Market Outlook
• 11.4. Key Market Forecast Assumptions
• 11.5. The United States Market Size
  • 11.5.1. The total market size of Behcet's Syndrome in the United States
  • 11.5.2. The market size of Behcet's Syndrome in the United States by Therapies
• 11.6. EU4 and the UK Market Size
  • 11.6.1. The total market size of Behcet's Syndrome in EU4 and the UK
  • 11.6.2. The market size of Behcet's Syndrome in EU4 and the UK by Therapies
• 11.7. Japan Market Size
  • 11.7.1. The total market size of Behcet's Syndrome in Japan
  • 11.7.2. The market size of Behcet's syndrome in Japan by Therapies

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access

• 15.1. The United States
  • 15.1.1. Medicare and Medicaid
  • 15.1.2. Private insurance
  • 15.1.3. Patient access program
• 15.2. Health Technology Assessment
  • 15.2.1. HAS
  • 15.2.2. IQWIG
  • 15.2.3. AEMPS

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology
• 16.3. Acronyms and Abbreviations

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight